glp-1 pediatric GLP-1R Agonists in Children Two Pediatric MASLD Publications: Call

(4) Avoiding triggers (fried foods, cream sauces, carbonation, large portions)

These findings confirmed that GLP-1RA had a certain influence on the occurrence and development of tumors

The inquiry suggests that an in-depth examination of this relationship is crucial for refining perioperative management strategies

GLP-1R/GIPR receptor activation in the brain also reduces appetite and promotes satiety, supporting development of liraglutide, semaglutide, and tirzepatide for weight loss

With integrated metabolic approaches gaining traction, primary care providers, endocrinologists, and diabetes educators will need to revise protocols and adopt longer-term management strategies

For patients who are tolerating the maximal therapeutic dose of a once-daily or twice-daily GLP-1 receptor agonist (exenatide 10 g twice daily, liraglutide 1.8 mg once daily, or lixisenatide 20 mg once daily) but who are changing to a once-weekly GLP-1 receptor agonist, we recommend starting dulaglutide once weekly or exenatide once weekly at the maximal therapeutic dose (dulaglutide 1.5 mg, exenatide 2 mg)